March 2006
Worldwide Biotech;Mar2006, Vol. 18 Issue 3, p4
Trade Publication
Reports on the collaboration between Saint Louis, Missouri-based Orion Genomics and researchers to discover novel epigenetic biomarkers. Use of DNA methylation technologies to identify biomarkers; Research into epigenetic biomarkers to be conducted; Corporate background of Orion Genomics.


Related Articles

  • Epigenetics Gains Momentum; Novartis Teams up with Orion. Morrison, Trista // BioWorld Today;10/12/2009, Vol. 20 Issue 196, p1 

    The article reports on the expected collaboration of Orion Genomics LLC with Novartis AG. It states that both companies are engaged in epigenetic biomarkers for use in diagnostics. It mentions that the collaboration will involve Orion's use of its MethyIScope technology to build high-resolution,...

  • New breast cancer biomarkers could lead to better treatment.  // Medical Technology & Devices Week;12/31/2007, Vol. 5 Issue 51, p2 

    This article announces the discovery of new breast cancer biomarkers by Orion Genomics. The Orion study, which analyzed DNA methylation, was published in "PLoS ONE." According to Jared Ordway, director of research and development (R&D) at Orion, these biomarkers may be critical in the...

  • New breast cancer biomarkers may lead to improved treatment. Pedersen, Amanda // Medical Device Daily;12/26/2007, Vol. 11 Issue 233, p1 

    The article reports on the discovery of new breast cancer biomarkers by Orion Genomics that it says may someday lead to earlier detection and possibly better treatment of cancer. The company claimed that it has discovered and validated the most frequent DNA alterations detected in breast cancer....

  • MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma.  // BMC Cancer;2012, Vol. 12 Issue 1, p218 

    The article discusses a study conducted to know the importance of promoter methylation of newly identified epigenetically silenced genes (GATA6, CD81) and revealing its relationship with epigenetic markers to understand glioblastoma biology. It has been informed that the study results found that...

  • Molecular Analysis of a Multistep Lung Cancer Model Induced by Chronic Inflammation Reveals Epigenetic Regulation of p16 and Activation of the DNA Damage Response Pathway. Blanco, David; Vicent, Silvestre; Fraga, Mario F.; Fernandez-Garcia, Ignacio; Freire, Javier; Lujambio, Amaia; Esteller, Manel; Ortiz-de-Solorzano, Carlos; Pio, Ruben; Lecanda, Fernando; Montuenga, Luis M. // Neoplasia;Oct2007, Vol. 9 Issue 10, p840 

    The molecular hallmarks of inflammation-mediated lung carcinogenesis have not been fully clarified, mainly due to the scarcity of appropriate animal models. We have used a silica-induced multistep lung carcinogenesis model driven by chronic inflammation to study the evolution of molecular...

  • Cancer epigenetics reaches mainstream oncology. Rodríguez-Paredes, Manuel; Esteller, Manel // Nature Medicine;Mar2011, Vol. 17 Issue 3, p330 

    Epigenetics is one of the most promising and expanding fields in the current biomedical research landscape. Since the inception of epigenetics in the 1940s, the discoveries regarding its implications in normal and disease biology have not stopped, compiling a vast amount of knowledge in the past...

  • Pancreatic Cancer Biomarkers and Their Implication in Cancer Diagnosis and Epidemiology. Verma, Mukesh // Cancers;2010, Vol. 2 Issue 4, p1830 

    Pancreatic cancer is the fourth most common cause of cancer-related mortality in the United States. Biomarkers are needed to detect this cancer early during the disease development and for screening populations to identify those who are at risk. In cancer, "biomarker" refers to a substance or...

  • C-Path expands offices, staff and programs. Moore, Philip S. // Inside Tucson Business;7/24/2006, Vol. 16 Issue 6, p18 

    The article reports that the Critical Path Institute (C-Path) has leased an office at the Cambric Corporate Center in Tucson, Arizona. C-Path is the nonprofit partnership of the University of Arizona, SRI International and the U.S. Food and Drug Administration. C-Path's first consortium is to...

  • Celera, Ipsen in research pact for growth failure R&D.  // Diagnostics & Imaging Week;11/29/2007, Vol. 10 Issue 48, p5 

    The article reports on a research collaboration of Celera with Ipsen to develop biomarker and pharmacogenomic tests for growth failure patients. The first stage of the collaboration will focus on the discovery and characterization of genetic markers relating to this disease. Assuming the initial...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics